Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT.

Abstract

6554 Background: SER-155 is an investigational, oral, live biotherapeutic product (LBP) comprised of 16 bacterial strains designed to decolonize gastrointestinal (GI) pathogens, improve epithelial barrier integrity, and modulate immune responses to prevent bloodstream infections (BSI). In the placebo-controlled cohort 2 of the phase 1b study, SER-155-001 (NCT04995653), SER-155 was generally well tolerated with a safety profile similar to placebo and the incidence of BSIs, a secondary endpoint, was significantly lower after treatment with SER-155 when compared to placebo. We report exploratory analyses of biomarkers of T cell expansion relevant for immune reconstitution after HCT. Methods: Participants were randomized 1:1 to receive 4 days of oral vancomycin (for microbiome conditioning) and 10 days of SER-155 or placebo/placebo administered pre-HCT (course 1) and post-neutrophil engraftment (course 2). Primary endpoints were safety and SER-155 strain engraftment (PK). Exploratory endpoints included plasma cytokine concentrations measured by ELISA and analysis of peripheral blood mononuclear cells (PBMCs) by flow cytometry. Results: Demographics were comparable across treatment arms. 34 of 45 randomized participants were treated and received allo-HCT (SER-155, 20; placebo, 14); 28 received course 2 (SER-155, 19; placebo, 9). SER-155 strain engraftment was observed in the peri-transplant period (median 11.5 strains after course 1) and post-HCT (median 11 strains after course 2 and HCT Day 100). Significant differences and trends in cytokines of systemic inflammation and immune homeostasis were observed relative to placebo prior to HCT Day 0 and post-HCT. On HCT Day 0, both arms had similar concentrations of IL7 and IL15 (Table 1). However, after course 2, and at HCT Day 100, significantly higher concentrations of IL7 were observed in the SER-155 arm relative to placebo (p=0.02, and p=0.003, respectively). In a preliminary analysis of PBMCs from a subset of participants, a high frequency of CD4+ T cells were observed in the SER-155 arm at the same timepoints. For homeostatic cytokine IL15, no significant differences were observed between arms. Conclusions: The significantly higher concentrations of IL7 with SER-155 treatment and observed frequency of CD4+ T cells support the potential role of the GI microbiome in promoting homeostatic expansion of peripheral T cells and immune reconstitution important for successful HCT. Clinical trial information: NCT04995653 . Median plasma IL7 and IL15 (pg/mL), SER-155 vs. placebo (generalized linear model). HCT Day or event SER-155 IL7 Placebo IL7 SER-155 IL15 Placebo IL15 D0 13.8 13.0 31.9 30.4 D7 15.1 14.6 50.9 62.6 D14 12.8 15.5 56.6 69.8 Post-neutrophil engraftment 13.4 9.0 16.3 15.4 Post-course 2 7.4* 3.9 6.2 9.1 D100 7.1** 3.5 6.2 6.2 *p<0.05, **p<0.01.